BlackRock’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.31M | Buy |
594,404
+161,202
| +37% | +$422K | ﹤0.01% | 4268 |
|
|
2026
Q1 | $1.01M | Sell |
433,202
-414
| -0.1% | -$983 | ﹤0.01% | 4346 |
|
|
2025
Q4 | $1.01M | Sell |
433,616
-1,152
| -0.3% | -$2.67K | ﹤0.01% | 4299 |
|
|
2025
Q3 | $817K | Hold |
434,768
| – | – | ﹤0.01% | 4348 |
|
|
2025
Q2 | $1.26M | Sell |
434,768
-47,314
| -10% | -$68.1K | ﹤0.01% | 4180 |
|
|
2025
Q1 | $347K | Sell |
482,082
-3,270
| -0.7% | -$2.76K | ﹤0.01% | 4484 |
|
|
2024
Q4 | $500K | Buy |
485,352
+532
| +0.1% | +$633 | ﹤0.01% | 4414 |
|
|
2024
Q3 | $650K | Buy |
484,820
+1,418
| +0.3% | +$1.9K | ﹤0.01% | 4267 |
|
|
2024
Q2 | $628K | Buy |
483,402
+6,506
| +1% | +$9.81K | ﹤0.01% | 4284 |
|
|
2024
Q1 | $820K | Sell |
476,896
-3,703
| -0.8% | -$5.8K | ﹤0.01% | 4252 |
|
|
2023
Q4 | $706K | Sell |
480,599
-1,210
| -0.3% | -$1.44K | ﹤0.01% | 4343 |
|
|
2023
Q3 | $583K | Sell |
481,809
-41,995
| -8% | -$58.2K | ﹤0.01% | 4384 |
|
|
2023
Q2 | $760K | Buy |
523,804
+33,991
| +7% | +$58.2K | ﹤0.01% | 4362 |
|
|
2023
Q1 | $710K | Buy |
489,813
+1,730
| +0.4% | +$2.9K | ﹤0.01% | 4446 |
|
|
2022
Q4 | $844K | Sell |
488,083
-204,055
| -29% | -$381K | ﹤0.01% | 4457 |
|
|
2022
Q3 | $1.39M | Buy |
692,138
+1,385
| +0.2% | +$1.38K | ﹤0.01% | 4357 |
|
|
2022
Q2 | $513K | Sell |
690,753
-1,103,328
| -61% | -$3.21M | ﹤0.01% | 4768 |
|
|
2022
Q1 | $15.6M | Sell |
1,794,081
-4,696
| -0.3% | -$48.1K | ﹤0.01% | 3327 |
|
|
2021
Q4 | $28.8M | Sell |
1,798,777
-3,751
| -0.2% | -$59.6K | ﹤0.01% | 3039 |
|
|
2021
Q3 | $33.2M | Buy |
1,802,528
+23,706
| +1% | +$380K | ﹤0.01% | 2930 |
|
|
2021
Q2 | $24.8M | Buy |
1,778,822
+2,226
| +0.1% | +$31.1K | ﹤0.01% | 3165 |
|
|
2021
Q1 | $26.2M | Buy |
1,776,596
+44,996
| +3% | +$792K | ﹤0.01% | 3036 |
|
|
2020
Q4 | $33.6M | Buy |
1,731,600
+654,438
| +61% | +$10.2M | ﹤0.01% | 2719 |
|
|
2020
Q3 | $12M | Buy |
1,077,162
+126,906
| +13% | +$1.5M | ﹤0.01% | 3123 |
|
|
2020
Q2 | $12.9M | Buy |
950,256
+69,025
| +8% | +$775K | ﹤0.01% | 3042 |
|
|
2020
Q1 | $7.12M | Buy |
881,231
+125,966
| +17% | +$1.11M | ﹤0.01% | 3170 |
|
|
2019
Q4 | $7.26M | Buy |
755,265
+76,316
| +11% | +$823K | ﹤0.01% | 3395 |
|
|
2019
Q3 | $7.2M | Buy |
678,949
+22,171
| +3% | +$234K | ﹤0.01% | 3369 |
|
|
2019
Q2 | $7.56M | Buy |
656,778
+235,691
| +56% | +$2.84M | ﹤0.01% | 3376 |
|
|
2019
Q1 | $5.39M | Buy |
421,087
+27,457
| +7% | +$291K | ﹤0.01% | 3379 |
|
|
2018
Q4 | $2.42M | Buy |
393,630
+21,161
| +6% | +$171K | ﹤0.01% | 3609 |
|
|
2018
Q3 | $3.92M | Buy |
372,469
+30,470
| +9% | +$354K | ﹤0.01% | 3571 |
|
|
2018
Q2 | $5.02M | Buy |
341,999
+89,698
| +36% | +$1.15M | ﹤0.01% | 3505 |
|
|
2018
Q1 | $3.6M | Buy |
252,301
+11,427
| +5% | +$139K | ﹤0.01% | 3521 |
|
|
2017
Q4 | $2.83M | Buy |
+240,874
| New | +$2.96M | ﹤0.01% | 3606 |
|
Other funds holding SPRO
GP
P
VCM
AI
VFT
GCP
BlackRock's SPRO Position: Q2 2026 in Review
BlackRock increased its Spero Therapeutics (SPRO) stake by 37% in Q2 2026, buying an estimated $422K and bringing the position to 594,404 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4268.
BlackRock first reported a position in SPRO in Q4 2017 and has held it in 35 quarters since. The position peaked at $33.6M in Q4 2020. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.
- BlackRock held 594,404 shares of Spero Therapeutics worth $1.31M as of Q2 2026.
- BlackRock bought 161,202 Spero Therapeutics shares in Q2 2026, an estimated $422K.
- Spero Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4268 holding.
- BlackRock first reported a position in Spero Therapeutics in Q4 2017 and has held it in 35 quarters since.
- BlackRock's Spero Therapeutics position peaked at $33.6M in Q4 2020.
- 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.